VHH ANTIBODY Service
End-to-end VHH development
& manufacturing
From immunization to GMP production, Eurogentec supports your VHH projects across all development stages, ensuring continuity from research to clinical manufacturing.
Whether you are initiating a new program or advancing an existing candidate, we help you progress efficiently toward clinical-grade material.
A single partner across
the entire VHH workflow
Developing VHH (also known as single-domain antibodies or nanobodies) requires expertise
across multiple stages from antigen-specific discovery to scalable, compliant production.
At Eurogentec, we support your project across key development steps, helping you move from research to GMP manufacturing
while ensuring consistency in quality and technical approach.
Flexible entry points for your project
Every VHH project is different and you don’t have to start from the beginning.
We support you at any stage:
Starting from scratch with antigen and immunization, advancing a selected VHH candidate
or moving directly to GMP production with an existing cell bank.
Our teams ensure a smooth transition between phases, minimizing delays and technical risks.
Discovery & research-grade
VHH production
We support the early phases of your VHH project, from Llama or Alpaca immunization to candidate selection and production. Our services include:
- Camelid immunization
- VHH library construction
- Screening and selection of high-affinity binders
- Recombinant VHH production (research grade)
GMP VHH manufacturing
For projects entering clinical development, Eurogentec has developed and uses a microbial platform for GMP-compliant VHH manufacturing, enabling rapid progression from research cell bank to GMP batch, typically within 8 months. Our capabilities include:
- Process transfer and scale-up
- Cell line development by Customer or managed by Eurogentec
- GMP production of VHH from cell banks in E. coli or P. pastoris (K. phaffii)
- Quality control and regulatory support
Explore our VHH services in detail
Whether you are starting from immunization or moving toward GMP manufacturing, discover our
dedicated services for each stage of your VHH project.
Frequently Asked Questions
What are VHH antibodies?
VHH antibodies, also known as single-domain antibodies, are derived from camelids such as llamas or alpacas. Their small size and stability make them particularly suitable for research, diagnostic, and therapeutic applications.
What is VHH manufacturing?
VHH manufacturing refers to the production of recombinant single-domain antibodies, from early discovery and screening to large-scale production under GMP conditions for clinical use.
Can Eurogentec support both VHH discovery and GMP manufacturing?
Yes, Eurogentec offers services covering early-stage VHH discovery, including immunization and screening, as well as GMP manufacturing for clinical applications.
Do I need a cell bank before starting GMP manufacturing?
Yes, GMP production requires a qualified cell bank. If you already have a research cell bank, it can be used as the starting point for GMP manufacturing.
Can Eurogentec help if I do not yet have a cell bank?
If your project is not yet ready for GMP manufacturing, our team can guide you on the steps required to prepare your VHH for production and discuss suitable options based on your project stage.
Can I start directly with GMP manufacturing?
Yes, if you already have a validated VHH candidate and a suitable cell bank, you can directly access our GMP manufacturing services.
What expression systems are used for VHH production?
Eurogentec uses microbial expression systems such as E. coli and P. pastoris (K. phaffii) to produce VHH antibodies efficiently and at scale.